Background: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects. Objective: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN). Methods: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN. Results: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found. Conclusion: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment. © 2013 S. Karger AG, Basel.
CITATION STYLE
Siepmann, D., Lotts, T., Blome, C., Braeutigam, M., Phan, N. Q., Butterfass-Bahloul, T., … Ständer, S. (2014). Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: Results of a randomized, hydrocortisone- controlled, double-blind phase II trial. Dermatology, 227(4), 353–360. https://doi.org/10.1159/000355671
Mendeley helps you to discover research relevant for your work.